ESG rating performance
Camurus is committed to improving the lives of patients with severe and chronic diseases through innovative, long-acting medicines. We prioritize sustainability throughout our value chain and are regularly evaluated by independent third-party ESG ratings.
Results
In October 2024 Camurus improved the company’s score in a rating by MSCI from an A to an AA in a scale ranging from CCC (laggard) to AAA (leader). With an AA ranking, considered a leader, Camurus is positioned above industry average.
MSCI uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers.*
In May 2024, Camurus received an ESG risk rating score of 21.8 by the Morningstar Sustainalytics, representing a medium risk of experiencing material financial impacts from ESG factors. Sustainalytics’ scale for medium risk ranges from 20-30. A score below 20 corresponds to the risk category low.**
Morningstar Sustainalytics provides environmental, social and governance (ESG) research, ratings and data to institutional investors and companies.
Score 21.8
Mediumby Morningstar Sustainalytics
Camurus’ sustainability (ESG) performance has been assessed by the rating company EthiFinance. In 2024, Camurus improved the company’s score from 73/100 in 2023 to 83/100 – thereby outperforming the of rated companies within the same industry according to EthiFinance.***
EthiFinance is a European rating, research and advisory group that provides financial decision makers with a comprehensive set of ESG ratings and data on listed European companies. The ESG ratings assess the way in which companies manage their ESG risks and how mature they are in their corporate sustainability journey.
Score
83/100by EthiFinance
* MSCI ESG Research LLC is a Registered Investment Adviser under the Investment Advisers Act of 1940 and a subsidiary of MSCI Inc. Neither MSCI nor any of its products or services recommends, endorses, approves or otherwise expresses any opinion regarding any issuer, securities, financial products or instruments or trading strategies and MSCI’s products or services are not a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such, provided that applicable products or services from MSCI ESG Research may constitute investment advice. The use by Camurus of any MSCI ESG Research LLC or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of Camurus by MSCI. MSCI services and data are the property of MSCI or its information providers and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or sercice marks of MSCI.
** In no event should the ESG rating result be considered an investment advice or expert opinion as defined by the applicable legislation. Copyright ©2024 Sustainalytics, a Morningstar company. All rights reserved. This section includes information and data provided by Sustainalytics and/or its content providers. Information provided by Sustainalytics is not directed to or intended for use or distribution to India-based clients or users and its distribution to Indian resident individuals or entities is not permitted. Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect. Use of such data is subject to conditions available at https://www.sustainalytics.com/legal-disclaimers/
*** The Ethifinance ESG rating report and rating results do not in any way constitute an "investment advice" within the meaning of article D.321-1 of the French Monetary and Financial Code, an "investment recommendation" within the meaning of article 3-1-35 of European Regulation No. 596/2014 of April 16, 2014 known as “Market Abuse”, nor more generally a recommendation or offer to buy or subscribe to, sell or hold or retain a security.